Biotech Startup Receives Funding to Pursue Cell-based Therapies for Neurological Disorders

Biotech Startup Receives Funding to Pursue Cell-based Therapies for Neurological Disorders

Startup company Oscine Therapeutics has received an investment from Sana Biotechnology to support the research and development of cell-based therapies for a variety of neurological disorders, including multiple sclerosis (MS).

This venture is based on work done over the past several decades in the lab of Steve Goldman, MD, PhD, co-director of the Center for Translational Neuromedicine, University of Rochester Medical Center (URMC).

“We are excited that the basic science discoveries made here at the Medical Center are the basis for innovative, first-in-class therapies that hold the potential to change the lives of people with these devastating neurodegenerative diseases,” said Steve Dewhurst, PhD, vice dean for research of the University of Rochester School of Medicine and Dentistry.

Goldman’s lab has been focused on understanding glia, a class of cell often called the “support cells” of the central nervous system. Unlike neurons, glia aren’t involved in directly sending electric signals in the brain, but they play a number of other roles, including providing protection and nutrients to neurons, and helping them send signals.

In some neurological disorders, such as MS and Huntington’s disease, a person’s glia are not working properly, or they are lost entirely over the course of the disease’s development.

“Neurological disorders are complex diseases,” Goldman said in a URMC press release, “but in many instances it appears that faulty support cells of the brain are driving the disease process. These diseases represent promising targets for cell-replacement therapies because we know a great deal about the role these cells play, how to create them, and how to get them to the areas of the brain where they are needed.”

Goldman’s work has specifically focused on using stem cells — either embryonic stem cells or induced pluripotent stem cells, which are stem cells that are “reverse engineered” from other cell types, like skin cells. By giving these stem cells the right chemical signals, they can be induced to grow and turn into glia, which could then potentially be used for therapies to replace the faulty and/or absent glia of a patient with a neurological disease.

“Cell-based therapies hold significant promise, and while progress has been made in areas such as cancer, there is a significant unmet need in diseases of the central nervous system,” said Christina Trojel-Hansen, PhD, CEO of Oscine and co-founder of the company with Goldman.

“The support from Sana will enable us to advance important research in this field, and work with an established team that has experience in bringing cell-based therapies through clinical trials and into clinical practice,” she concluded.

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
follow me
×
Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
follow me
Latest Posts
  • imaging and prognosis
  • database study
  • AllianceRx Walgreens Prime
  • opioid addiction and ms

18 comments

  1. Wonderful. If I understood, . . . finally, an uplifting report that addresses MS curative reversal as opposed to years of your reports’ address to treating symptoms and watching ourselves in hopeless decline. I pray to the Archangels for these scientists in Rochester.

    • Peggy says:

      We prayed for our beautiful daughter to have MS. She’s recently been diagnosed with ALS. Is there anything being done for those with ALS?

  2. David G. Maskalick, Ph. D. says:

    This would be very exciting news if the glia cells help to recreate the myelin sheath after demyelination and/or recreate nerve cells lost due to atrophy. I wonder whether this is anticipated.

  3. Jenny Cann says:

    My son had ppms he has no help no physio i am watching him deteriorate and cant do a thing about it. Bless your team and look forward to further promising results.

    • Patricia Goodin says:

      This sounds like a blessing from GOD if you need volunteers during the trial times please please sign me up. GOD bless you .

  4. Wendy Bisesi says:

    I hope Complex Regional pain syndrome is added to this study as well. We suffer greatly with our nerve cells and faulty support cells. We are a rare disease; often not considered in research.

  5. John Smith says:

    Biotechnology is a technology that is fundamentally based on the biology of living organisms and uses biological processes to develop new products and solutions for the better healthcare of the patients and the society as a whole. Biotechnology has boomed a lot in recent times and so the biotech stocks recently. Even in Australia, I have seen the boom of AI and biotechnology rapidly. Other than Oscine there are many other biotech companies listed in ASX as well that are growing good. I have recently read news about the same at Kalkine

  6. Marilee Chipoletti says:

    I’m excited about all the new research and have participated in a few studies. I am interested in participating in this study when it becomes available. Please keep me in mind. I have ppms.

Leave a Comment

Your email address will not be published. Required fields are marked *

Pin It on Pinterest

Share This